| ¿µ¹® | adverse effect | ÇÑ±Û | ¿ªÈ¿°ú, À¯ÇØÈ¿°ú |
|---|---|---|---|
| ¼³¸í | ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇÏ´Â Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, ƯÈ÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀÎ ¿ªÈ¿°ú·Î¼ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | vaccination | ÇÑ±Û | ¿¹¹æÁ¢Á¾ |
|---|---|---|---|
| ¼³¸í | 1.ÀÎÀ§ÀûÀ¸·Î ´Éµ¿¸é¿ªÀ» ¼º¸³½ÃÄѼ °¨¿°¿¡ ´ëÇÑ ÀúÇ×·ÂÀ» ³ôÀ̱â À§ÇÏ¿© ¾àµ¶Èº´¿øÃ¼(»ý¹é½Å) ¶Ç´Â »ç±Õ, ºÒȰ¼º ȹé½Å µîÀ» Á¢Á¾ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. ´çÃÊ Á¾µÎ´Â Á¨³Ê(Jenner)¿¡ ÀÇÇØ¼ ¹ß°ßµÈ ¸¶¸¶ ¿¹¹æ¹ý¿¡ °üÇÑ Á¢Á¾À» ÀǹÌÇßÀ¸³ª ÇöÀç¿¡´Â ³Î¸® °¨¿°ÁõÀ̳ª Àü¿°º´ÀÇ º´¿ø±Õ ±× ÀÚü°¡ ÀϺθ¦ Á¢Á¾Çؼ ºñ°¨¿°ÀÚ¸¦ ¸é¿ªÇÏ´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¿¹¹æÁ¢Á¾À¸·Î Ç¥ÁØÈµÇ¾úÀ¸¸ç, Ç׿øÀ¸·Î¼ ¹é½ÅÀÌ »ç¿ëµÈ´Ù. ¿¹¹æÁ¢Á¾À¸·Î °¨¿°ÀÌ ¾ïÁ¦µÇÁö¸¸ ÇǺο¡ ³ªÅ¸³ª´Â ÀÌ»óÀ̳ª µÎµå·¯±â¸ð¾ç È«¹Ý µîÀÇ ÇǺιßÁøÀ̳ª ³ú¿° µîÀÇ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀǸ¦ ¿äÇÑ´Ù. 2.¿¹¹æÁ¢Á¾¿¡ ¾²ÀÌ´Â Ç׿ø¿¡´Â Å©°Ô ³ª´©¾î ¼¼±Õ¼º Ç׿ø°ú ¹ÙÀÌ·¯½º¼º Ç׿øÀÌ Àִµ¥, ¼¼±Õ¼º Ç׿ø¿¡´Â »ç¸êµÈ Àüü ¼¼±Õ(¹éÀÏÇØ ¹é½Å µî), º´¿øÃ¼°¡ ü¿Ü·Î ¹èÃâÇÏ´Â µ¶¼Ò¸¦ ¸êµ¶ÇÑ º¯¼ºµ¶¼Ò(Åå¼ÒÀ̵å)(µðÇÁÅ׸®¾Æ-ÆÄ»ódz µî), µ¶·ÂÀ» ¾àȽÃŲ »ý¼¼±Õü(BCG µî)µîÀÌ ÀÖ°í, ¹ÙÀÌ·¯½º¼º Ç׿ø¿¡´Â »ý¾àµ¶ÈÇÑ °Í(¼Ò¾Æ¸¶ºñ)°ú »ç¸êµÈ ¹é½Å(ÀÎÇ÷翣ÀÚ) µîÀÌ Æ÷ÇԵȴÙ. Çѱ¹¿¡¼´Â Àü¿°º´ ¿¹¹æ¹ý¿¡ µÎâ-µðÇÁÅ׸®¾Æ-¹éÀÏÇØ-ÀåÆ¼Çª½º-ÄÝ·¹¶ó-ÆÄ»ódz-°áÇÙ µî Àϰö °³ Áúº´¿¡ °üÇÏ¿© Á¤±â ¿¹¹æÁ¢Á¾À» ½ÃÇàÇϵµ·Ï µÇ¾î ÀÖ´Ù. ¶Ç ´ëÇѼҾưúÇÐȸ¿¡¼´Â BCG-¼Ò¾Æ¸¶ºñ-µðÇÁÅ׸®¾Æ-¹éÀÏÇØ-ÆÄ»ódz-È«¿ª-À¯Ç༺±Í¹Ø»ù¿°(º¼°Å¸®)-dzÁø-ÀϺ»³ú¿° µî ¾ÆÈ© °³ ¿¹¹æÁ¢Á¾À» Á¤Çϰí ÀÖ´Ù. |
||
| ¿µ¹® | immunological reaction | ÇÑ±Û | ¸é¿ª¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | »ýüÀÇ ¸ö ¾È¿¡¼ »ý±ä ¹°ÁúÀ̳ª ¸ö ¹Û¿¡¼ µé¾î¿Â ¹°ÁúÀÌ »ýü¿Í ´Ù¸¦ ¶§ ÀÚ±â ü³»ÀÇ ÅëÀϼº°ú °³Ã¼ÀÇ »ýÁ¸ À¯Áö ¹× Á¾ÀÇ Á¸¼ÓÀ» À§ÇÏ¿© ±× ¹°ÁúµéÀ» Á¦°ÅÇÏ´Â ÀÏ·ÃÀÇ »ýü ¹ÝÀÀ. ´Ù½Ã ¸»ÇØ B¼¼Æ÷¿¡ ÀÇÇÑ Ç×ü»ý»ê, T¼¼Æ÷¸¦ Áß½ÉÀ¸·Î ÇÏ´Â ¼¼Æ÷¼º ¸é¿ª, ¸é¿ª°ü¿ë, ¸é¿ª±â¾ï µîÀÇ »ýü ³» ¹ÝÀÀÀ» ¸»ÇÑ´Ù. Å«Æ÷½Ä¼¼Æ÷´Â Ç׿øÀ» ó¸®Çؼ ƯÀÌÀûÀÎ Ç׿ø°áÁ¤±â¸¦ °®´Â ºÐÀÚ·Î ¹Ù²ã, Ç׿ø°ú ÁÖ¿äÁ¶Á÷ ÀûÇÕÀ¯ÀüÀÚº¹ÇÕü¸¦ ¼¼Æ÷Ç¥¸é¿¡ Ç¥ÇöÇϸç, T¼¼Æ÷·Î Àü´ÞÇÑ´Ù. ÇÑÆí B¼¼Æ÷´Â Å«Æ÷½Ä¼¼Æ÷ ³»¿¡¼ ó¸®µÈ Ç׿øÀÇ °áÁ¤±â¸¦ ÀνÄÇÏ¿© ´ëÀÀÇϴ ƯÀÌÀûÇ×ü¸¦ »ý»êÇÏ¿© Ç׿øÀ» ó¸®ÇÑ´Ù. |
||
| ¿µ¹® | reaction formation | ÇÑ±Û | ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º |
|---|---|---|---|
| ¼³¸í | ¾ï¾Ðº¸´Ù ´õ Àû±ØÀûÀÎ ¹æ¾î¸ÞÄ¿´ÏÁòÀ̸ç, ¹«ÀǽÄÀûÀÎ »ý°¢, ¼Ò¿ø, Ãæµ¿ÀÌ ³Ê¹«³ªµµ ¹Þ¾Æµé¿©Áú ¼ö ¾ø´Â °ÍÀÏ °æ¿ì¿¡ À̿ʹ Á¤¹Ý´ë ¹æÇâÀÇ °ÍÀ» °Á¶ÇÔÀ¸·Î½á ±×·± ¹«ÀǽÄÀûÀÎ °ÍµéÀÌ ÀǽĵÇÁö ¾Ê°Ô ÇÏ´Â °úÁ¤. ¿¹¸¦ µé¸é °¡Àå °¡ÇÐÀûÀÎ ¼º°ÝÀÇ »ç¶÷ÀÌ »ýÃ¼ÇØºÎ ¹Ý´ë·ÐÀÚ°¡ µÇ´Â °æ¿ì¸¦ µé ¼ö ÀÖ´Ù. À̰ÍÀº ¶Ç °¡½¿ ±íÀÌ Àá°ÜÀÖ´Â µÎ·Á¿òÀÌ ÀǽĵǴ °ÍÀ» ÇÇÇϱâ À§Çؼ µÎ·Á¿òÀÇ ´ë»óÀÌ µÇ´Â Çൿ¿¡ °ñ¸ôÇÏ´Â °æ¿ìµµ Æ÷ÇÔÀÌ µÈ´Ù. ¿¹¸¦ µé¸é, ³²ÀÚ¿¡°Ô »óó¹ÞÁö ¾ÊÀ»±î ÇÏ´Â µÎ·Á¿ò¿¡ °¡µæ Âù ¼Ò³à°¡ ÀÌ °°Àº µÎ·Á¿òÀ» ºÎÁ¤ÇÏ·Á´Â ¼ö´ÜÀ¸·Î ³ÀâÇÑ ¼ºÇàÀ§¿¡ °ñ¸ôÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¶Ç ÀüóÀÇ Àڳฦ ¹Ì¿öÇÏ´Â °è¸ð°¡ ¿ÀÈ÷·Á Áö³ªÄ¥ Á¤µµ·Î ±× ¾ÆÀ̸¦ ±Í¿©¿öÇÏ´Â ÀÏ µûÀ§ÀÌ´Ù. |
||
| ¿µ¹® | complement fixation reaction | ÇÑ±Û | º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ ÀÖ¾î¼ º¸Ã¼¿Í °áÇÕÇÏ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇÏ´Â ¿ëÇ÷¼ÒÀÇ È¥ÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀÏ¾î³ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉÃ, Ŭ¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ. |
||
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
|---|---|
| ARMS | adverse reaction monitoring system; amplification refractory mutation system |
| SADR | suspected adverse drug reaction |
| vacc | vaccination |
| VS | vaccination scar; vaccine serotype; vagal stimulation; vasospasm; venesection; ventricular septum; v... |
| PV | post vaccination |
|---|---|
| ADR | Adverse Drug Reaction |
| ADE | Adverse Drug Event |
| AE | Adverse events |
| AE | Adverse effects |
primary's area
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
|---|---|
| adverse reaction | Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen. (05 Mar 2000) |
| adverse | Harmful. (18 Nov 1997) |
| adverse effect | This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical. (09 Oct 1997) |
| adverse event | A toxic reaction to a medical therapy. (09 Oct 1997) |
| no-observed-adverse-effect level | The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed) (12 Dec 1998) |
| event, adverse | In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug. (12 Dec 1998) |
| malignant smallpox | Malignant smallpox, usually of the haemorrhagic form. Synonym: malignant smallpox. Variola miliaris, a form of varioloid in which the eruption consists of miliary vesicles without the formation of pustules. (05 Mar 2000) |
| West Indian smallpox | A mild form of smallpox caused by a less virulent strain of the virus. Synonym: Cuban itch, Kaffir pox, milkpox, pseudosmallpox, pseudovariola, variola minor, West Indian smallpox, whitepox. Origin: Pg. Alastrar, to scatter over (05 Mar 2000) |
| confluent smallpox | A severe form in which the lesions run into each other, forming large suppurating areas. (05 Mar 2000) |
| haemorrhagic smallpox | A severe and frequently fatal form of smallpox accompanied by extravasation of blood into the skin in the early stage, or into the pustules at a later stage, accompanied often by nosebleed and haemorrhage from other orifices of the body. Synonym: fulminating smallpox, variola haemorrhagica. (05 Mar 2000) |
| smallpox | <disease, virology> This acute viral disease once claimed a high mortality rate, but was officially announced as globally eradicated in 1979. This was due to who vaccination programs. Headache, vomiting and fever precede, the eruption of a widespread rash that is raised, vesicular and finally pustular. The eruption follows a set pattern of dissemination, commencing on the head and face. When the final stage is passed scars (pockmarks) are left to disfigure the skin. (27 Sep 1997) |
| smallpox vaccine | A live vaccinia virus vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (12 Dec 1998) |
| smallpox virus | <virology> Virus responsible for smallpox. Said to have been completely eradicated. Large DNA virus (brick like, 250-390nm x 20-260nm) with complex outer and inner membranes (not derived from plasma membrane of host cell). (18 Nov 1997) |
| discrete smallpox | The usual form in which the lesions are separate and distinct from each other. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|